Healthcare Industry News:  Thermage 

Devices Litigation

 News Release - June 20, 2007

Thermage Sues Alma Lasers for Patent Infringement

10 Thermage U.S. Patents Asserted

HAYWARD, Calif., June 20 (HSMN NewsFeed) -- Thermage, Inc. (Nasdaq: THRM ), a leader in non-invasive tissue tightening in the aesthetic industry, today announced that it has filed a patent infringement lawsuit against Alma Lasers, Ltd. and Alma Lasers, Inc. in Delaware Federal District Court. The lawsuit claims that 10 Thermage U.S. patents, covering Thermage's innovative skin tightening and contouring technology, are infringed by Alma's Accent XL product, and six of those patents are infringed by Alma's Harmony product. In addition to damages and attorney fees, Thermage is asking the Court to enjoin Alma from further infringement.

"Several of the patents Alma infringes are the same as those admitted in 2005 by Syneron, Inc. as valid in a paid license settlement of prior litigation between Thermage and Syneron," said Stephen Fanning, President and Chief Executive Officer of Thermage. "We notified Alma as early as February 2006 that its Accent product in particular would infringe our patents if marketed in the United States. We were disappointed to hear in late April 2007 of Alma's receipt of FDA clearance for Accent XL, and Alma's intent to market this product in the U.S. in disregard of our patents. We are extremely confident our patents will be upheld by the Court and that Alma will be ordered to cease its infringement."

Thermage pioneered the use of radiofrequency energy to tighten skin while cooling the epidermis, and has been a leader in the non-ablative skin tightening field since its initial product introduction in 2002. To date, Thermage has 30 issued U.S. patents, 18 foreign issued patents, and numerous patent applications pending worldwide.

About Thermage, Inc.

Thermage's innovative technology provides a unique non-invasive procedure designed to tighten and contour skin, significantly expanding the non-invasive aesthetic applications physicians can offer to the rapidly growing "anti-aging" market. For more information, call 1-510-259-7117 or visit

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning Thermage's confidence that its patents will be upheld by the Court and that Alma will be ordered to cease its actions constitute such forward-looking statements. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect Thermage's business are detailed in the Company's Form 10-Q for the period ended March 31, 2007. Undue reliance should not be placed on forward-looking statements, which speaks only as of the date they are made. Thermage undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

Source: Thermage

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.